Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson’s Disease. A Systematic Review

MLA

Piniel Alphayo Kambey, et al. “Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson’s Disease. A Systematic Review.” Frontiers in Aging Neuroscience, vol. 13, Feb. 2021. EBSCOhost, https://doi.org/10.3389/fnagi.2021.645583.

APA

Piniel Alphayo Kambey, Kouminin Kanwore, Abiola Abdulrahman Ayanlaja, Iqra Nadeem, YinZhen Du, Wokuheleza Buberwa, WenYa Liu, & Dianshuai Gao. (2021). Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson’s Disease. A Systematic Review. Frontiers in Aging Neuroscience, 13. https://doi.org/10.3389/fnagi.2021.645583

Chicago

Piniel Alphayo Kambey, Kouminin Kanwore, Abiola Abdulrahman Ayanlaja, Iqra Nadeem, YinZhen Du, Wokuheleza Buberwa, WenYa Liu, and Dianshuai Gao. 2021. “Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson’s Disease. A Systematic Review.” Frontiers in Aging Neuroscience 13 (February). doi:10.3389/fnagi.2021.645583.